These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 36527386)

  • 1. Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906.
    Jungnik A; Arrubla Martinez J; Plum-Mörschel L; Kapitza C; Lamers D; Thamer C; Schölch C; Desch M; Hennige AM
    Diabetes Obes Metab; 2023 Apr; 25(4):1011-1023. PubMed ID: 36527386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon-like peptide-1 receptor agonist, in healthy Japanese men with overweight/obesity.
    Yazawa R; Ishida M; Balavarca Y; Hennige AM
    Diabetes Obes Metab; 2023 Jul; 25(7):1973-1984. PubMed ID: 36974349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials.
    Tillner J; Posch MG; Wagner F; Teichert L; Hijazi Y; Einig C; Keil S; Haack T; Wagner M; Bossart M; Larsen PJ
    Diabetes Obes Metab; 2019 Jan; 21(1):120-128. PubMed ID: 30091218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of the ghrelin-O-acyltransferase inhibitor BI 1356225 in overweight/obesity: Data from two Phase I, randomised, placebo-controlled studies.
    Bianzano S; Henrich A; Herich L; Kalsch B; Sarubbi D; Seitz F; Forst T
    Metabolism; 2023 Jun; 143():155550. PubMed ID: 36958671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.
    Urva S; Coskun T; Loh MT; Du Y; Thomas MK; Gurbuz S; Haupt A; Benson CT; Hernandez-Illas M; D'Alessio DA; Milicevic Z
    Lancet; 2022 Nov; 400(10366):1869-1881. PubMed ID: 36354040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, safety, tolerability and efficacy of cotadutide, a glucagon-like peptide-1 and glucagon receptor dual agonist, in phase 1 and 2 trials in overweight or obese participants of Asian descent with or without type 2 diabetes.
    Asano M; Sekikawa A; Kim H; Gasser RA; Robertson D; Petrone M; Jermutus L; Ambery P
    Diabetes Obes Metab; 2021 Aug; 23(8):1859-1867. PubMed ID: 33908687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.
    Thomas L; Martel E; Rist W; Uphues I; Hamprecht D; Neubauer H; Augustin R
    Diabetes Obes Metab; 2024 Jun; 26(6):2368-2378. PubMed ID: 38560764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
    Coskun T; Sloop KW; Loghin C; Alsina-Fernandez J; Urva S; Bokvist KB; Cui X; Briere DA; Cabrera O; Roell WC; Kuchibhotla U; Moyers JS; Benson CT; Gimeno RE; D'Alessio DA; Haupt A
    Mol Metab; 2018 Dec; 18():3-14. PubMed ID: 30473097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
    Ambery P; Parker VE; Stumvoll M; Posch MG; Heise T; Plum-Moerschel L; Tsai LF; Robertson D; Jain M; Petrone M; Rondinone C; Hirshberg B; Jermutus L
    Lancet; 2018 Jun; 391(10140):2607-2618. PubMed ID: 29945727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
    Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
    BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity.
    Friedrichsen MH; Endahl L; Kreiner FF; Goldwater R; Kankam M; Toubro S; Nygård SB
    Mol Metab; 2023 Dec; 78():101801. PubMed ID: 37690519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes.
    Saxena AR; Frias JP; Gorman DN; Lopez RN; Andrawis N; Tsamandouras N; Birnbaum MJ
    Diabetes Obes Metab; 2023 Oct; 25(10):2805-2814. PubMed ID: 37311722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity.
    Winther JB; Holst JJ
    Diabetes Obes Metab; 2024 Sep; 26(9):3501-3512. PubMed ID: 38853300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-daily oral small-molecule glucagon-like peptide-1 receptor agonist lotiglipron (PF-07081532) for type 2 diabetes and obesity: Two randomized, placebo-controlled, multiple-ascending-dose Phase 1 studies.
    Buckeridge C; Tsamandouras N; Carvajal-Gonzalez S; Brown LS; Hernandez-Illas M; Saxena AR
    Diabetes Obes Metab; 2024 Aug; 26(8):3155-3166. PubMed ID: 38751362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.
    le Roux CW; Steen O; Lucas KJ; Startseva E; Unseld A; Hennige AM
    Lancet Diabetes Endocrinol; 2024 Mar; 12(3):162-173. PubMed ID: 38330987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates.
    Elvert R; Herling AW; Bossart M; Weiss T; Zhang B; Wenski P; Wandschneider J; Kleutsch S; Butty U; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Lorenz M; Keil S; Larsen PJ
    Diabetes Obes Metab; 2018 Aug; 20(8):1836-1851. PubMed ID: 29938884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adaptive infusion of a glucagon-like peptide-1/glucagon receptor co-agonist G3215, in adults with overweight or obesity: Results from a phase 1 randomized clinical trial.
    Hope DCD; Ansari S; Choudhury S; Alexiadou K; Tabbakh Y; Ilesanmi I; Lazarus K; Davies I; Jimenez-Pacheco L; Yang W; Ball LJ; Malviya R; Reglinska B; Khoo B; Minnion J; Bloom SR; Tan TM
    Diabetes Obes Metab; 2024 Apr; 26(4):1479-1491. PubMed ID: 38229453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy.
    Zimmermann T; Thomas L; Baader-Pagler T; Haebel P; Simon E; Reindl W; Bajrami B; Rist W; Uphues I; Drucker DJ; Klein H; Santhanam R; Hamprecht D; Neubauer H; Augustin R
    Mol Metab; 2022 Dec; 66():101633. PubMed ID: 36356832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual glucagon-like peptide-1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity.
    Golubic R; Kennet J; Parker V; Robertson D; Luo D; Hansen L; Jermutus L; Ambery P; Ryaboshapkina M; Surakala M; Laker RC; Venables M; Koulman A; Park A; Evans M
    Diabetes Obes Metab; 2024 Jul; 26(7):2634-2644. PubMed ID: 38562018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.